Search Results - "Grote, Thomas H."

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist by Navari, Rudolph M, Reinhardt, Rick R, Gralla, Richard J, Kris, Mark G, Hesketh, Paul J, Khojasteh, Ali, Kindler, Hedy, Grote, Thomas H, Pendergrass, Kelly, Grunberg, Steven M, Carides, Alexandra D, Gertz, Barry J

“…Patients consistently report that vomiting and nausea are among the most unpleasant and distressing aspects of chemotherapy. 1 Vomiting due to anticancer drugs…”
Get full text

Secondary immune thrombocytopenia (ITP) as an initial presentation of Whipple’s disease by Priest, David H., Grote, Thomas H., Staley, Sallie L., Berger, William S., Norman, Elizabeth S., Smith, Brian S.

“…Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease characterized by low platelet count that has been associated with a number of chronic…”
Get full text

Identifying BRAF mutations in colorectal cancer (CRC) by initial immunohistochemical (IHC) staining for mismatched protein expression as part of a Lynch syndrome screening program: A distinct clinicopathologic entity by Grote, Thomas H., Kilpatrick, Scott E., Webb, Dena B., Hughes, Amy Herndon, Hughes, Sarah

“…Abstract only 405 Background: Multiple genetic mutations resulting in different clinical phenotypes have been found in colorectal adenocarcinoma. Mutation in…”
Get full text

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting: Pooled analysis of 14 clinical trials by WHITMORE, J. B, KRIS, M. G, HESKETH, P. J, GROTE, T. H, DUBOIS, D. M, CRAMER, M. B, HAHNE, W. F

“…Dolasetron mesilate is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting. For the majority of…”
Get full text

Randomized, double blind, dose‐response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy by Rubenstein, Edward B, Gralla, Richard J., Hainsworth, John D., Hesketh, Paul J., Grote, Thomas H., Modiano, Manuel R., Khojasteh, Ali, Kalman, Leonard A., Benedict, Claude R., Hahne, William F.

“…BACKGROUND This double blind parallel group study assessed the acute antiemetic efficacy of four oral doses of dolasetron mesylate in cancer patients receiving…”
Get full text

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone by Kris, M G, Pendergrass, K B, Navari, R M, Grote, T H, Nelson, A M, Thomas, V, Ferguson, B B, Allman, D S, Pizzo, B A, Baker, T W, Fernando, I J, Chernoff, S B

“…Dolasetron is a 5-HT3 antagonist antiemetic with active oral and intravenous formulations. The effects of this class are enhanced when combined with…”
Get more information

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting by Whitmore, J. B., Kris, Mark G., Hesketh, Paul J., Grote, Thomas H., DuBois, Dawn M., Cramer, Michael B., Hahne, William F.

Get full text

Primary lymphoma of the central nervous system. A report of 20 cases and a review of the literature by Grote, T H, Grosh, W W, List, A F, Wiley, R, Cousar, J B, Johnson, D H

“…Twenty patients with primary non-Hodgkin's lymphoma of the central nervous system (CNS) were seen at Vanderbilt and its affiliated hospitals between 1974 and…”
Get more information